CCNU (Lomustine)
From Glioblastoma Treatments
| Property | Information |
|---|---|
| Drug Name | CCNU (Lomustine) |
| FDA Approval | Yes |
| Used for | Glioblastoma |
| Clinical Trial Phase | Phase 3 (Germany) |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Hematological toxicity, nausea, vomiting, and pulmonary toxicity |
| OS without | Not specified |
| OS with | 23 months median survival, with 47% at 2 years |
| PFS without | Not specified |
| PFS with | Not specified |
| Usefulness Rating | 4 |
| Usefulness Explanation | Not specified |
| Toxicity Level | Not specified |
| Toxicity Explanation | Not specified |
Notes: A combination of TMZ with CCNU showed promising results including a 5-year survival rate of 16% among a small patient cohort. MGMT methylation status significantly influenced outcomes.
From Ben Williams Book: Not specified
Loading comments...
